Drug details

Jaypirca (pirtobrutinib tablets)

type of Antineoplastic Tyrosine Kinase Inhibitors

Jaypirca (pirtobrutinib) is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.

This drug may have the following side effects:

• hives, 
• difficulty breathing, 
• swelling of your face, lips, tongue, or throat, and 
• abnormal blood lab results (decreased neutrophil count, lymphocyte count and platelet count)

The following drugs are related to Jaypirca, either as a replacement or used together:

• Abecma (idecabtagene vicleucel suspension)
• Calquence (acalabrutinib capsules)
• Actemra (tocilizumab injection)
• Afinitor (everolimus tablets)
• Afinitor Disperz (everolimus tablets)
• Akynzeo (netupitant and palonosetron capsules)
• Alecensa (alectinib capsules)
• Aliqopa (copanlisib for injection, for intravenous use)
• Arzerra (ofatumumab injection)
• Blincyto (blinatumomab for injection)
• Cablivi (caplacizumab-yhdp injection)
• Carvykti (ciltacabtagene autoleucel for iv injection)
• Columvi (glofitamab-gxbm injection)
• Tafinlar (dabrafenib capsules)
• Darzalex Faspro (daratumumab and hyaluronidase-fihj injection)
• Darzalex (daratumumab intravenous injection)